Developmental arsenic exposure impairs cognition, directly targets DNMT3A, and reduces DNA methylation

Developmental arsenic exposure has been associated with cognitive deficits in epidemiological studies, but the underlying mechanisms remain poorly understood. Here, we establish a mouse model of developmental arsenic exposure exhibiting deficits of recognition and spatial memory in the offspring. These deficits are associated with genome-wide DNA hypomethylation and abnormal expression of cognition-related genes in the hippocampus. Arsenic atoms directly bind to the cysteine-rich ADD domain of DNA methyltransferase 3A (DNMT3A), triggering ubiquitin- and proteasome-mediated degradation of DNMT3A in different cellular contexts. DNMT3A degradation leads to genome-wide DNA hypomethylation in mouse embryonic fibroblasts but not in non-embryonic cell lines. Treatment with metformin, a first-line antidiabetic agent reported to increase DNA methylation, ameliorates the behavioral deficits and normalizes the aberrant expression of cognition-related genes and DNA methylation in the hippocampus of arsenic-exposed offspring. Our study establishes a DNA hypomethylation effect of developmental arsenic exposure and proposes a potential treatment against cognitive deficits in the offspring of pregnant women in arsenic-contaminated areas.

Automated summary

This study establishes a mouse model of developmental arsenic exposure and finds that arsenic exposure leads to deficits in recognition and spatial memory in the offspring. These deficits are associated with DNA hypomethylation and abnormal expression of cognition-related genes in the hippocampus. The study also reveals that arsenic atoms directly bind to the ADD domain of DNMT3A, leading to its degradation and genome-wide DNA hypomethylation.